CAS: 2304-98-5; (S)-2-(((Benzyloxy)Carbonyl)Amino)-5-(3-Nitroguanidino)Pentanoic Acid

该化合物是一种硝基甲基因衍生物,通常用于peptide合成和生化研究,该化合物的特点是,作为Guanidine功能保护组,作为合成程序期间的稳定性的保护组,在正丙胺侧链上作为保护组,其Z(苯氧碳基)保护组进一步促进了固相peptide合成(SPPS)中的受控脱保.该试剂对于研究硝基氧化物合成酶抑制剂(NOS)尤其有用,因为它能够调节依赖线的路径.高纯度和连续性能使其适合在酶学,药用化学和蛋白质学研究中的应用.建议在水下进行适当处理以保持再活动.

结构式图片

上下游产品

CAS号2149-70-4 Nω-硝基-L-精氨酸 | CAS号501-53-1 氯甲酸苄酯 | CAS号74-79-3 L-精氨酸 | CAS号1119-34-2 L-精氨酸盐酸盐 | CAS号33515-09-2 黄体生成激素释放激素(LHRH) | CAS号74-79-3 L-精氨酸 | CAS号2896-20-0 H-Arg-Val-OH ac... | CAS号15706-88-4 ARG-ASP | CAS号123847-40-5 ethyl 4-[[2-[[4... | CAS号2047-13-4 H-ARG-PHE-OH | CAS号1188-24-5 H-ARG-LEU-OH | CAS号15706-89-5 H-ARG-GLU-OH | CAS号75957-60-7 斯耐潘定 | CAS号40968-46-5 H-ARG-LYS-OH

合成工艺路线路线简述

    📜L-精氨酸盐酸盐置于sodium Hydroxide,硫酸,三氧化硫,硝酸,二氧化氮体系中,化学反应生成Nα-Cbz-Nω-硝基-L-精氨酸
    参考文献:Gibian,H.; Schroeder,E.,Justus Liebigs Annalen Der Chemie,1961,Vol. 642,P. 145-162
    标题:Gibian,H.; Schroeder,E.,Justus Liebigs Annalen Der Chemie,1961,Vol. 642,P. 145-162

    海关参考信息

    专利信息


    专利号:US-4704450-A
    优先权日:1983-02-21
    标 题 :Synthesis of hpGRF(Somatocrinin) in liquid phase and intermediate peptides
    发明人:DIAZ JOSEPH; DEMARNE HENRI; RONCUCCI ROMEO; SCHMELCK PAUL-HENRY
    权利人:SANOFI SA
    摘要:The invention relates to synthesis of hpGRF (Somatocrinin) in liquid phase and to intermediate peptides, comprising: coupling, one after the other and in the order of the sequence of the GRF, the fragments in which: (a) the side acid functions of the aspartic and glutamic acids and the side amine function of the lysine are protected by protector groups stable in the conditions of deprotection of the group Boc, (b) the guanidine function of the arginine is protected by protonation, and (c) the N-terminal amino acid is protected on the amine by the Boc group; selectively eliminating the group Boc from the N-terminal amine of the peptide in phase of elongation by hydrolysis with trifluoroacetic acid, said coupling being effected in an aprotic polar solvent and eliminating, at the end of sequence, all the protector groups by hydrolysis with the aid of a 0.1 to 1M solution of methanesulfonic or trifluoromethanesulfonic acid in trifluoroacetic acid.

    专利号:US-4581168-A
    优先权日:1983-02-21
    标题:Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides
    发明人:DIAZ JOSEPH; DEMARNE HENRI; RONCUCCI ROMEO; SCHMELCK PAUL-HENRY
    权利人:SANOFI SA
    摘要:The invention relates to synthesis of hpGRF (Somatocrinin) in liquid phase and to intermediate peptides, comprising:--coupling, one after the other and in the order of the sequence of the GRF, the fragments in which: (a) the side acid functions of the aspartic and glutamic acids and the side amine function of the lysine are protected by protector groups stable in the conditions of deprotection of the group Boc, (b) the guanidine function of the arginine is protected by protonation, and (c) the N-terminal amino acid is protected on the amine by the Boc group;--selectively eliminating the group Boc from the N-terminal amine of the peptide in phase of elongation by hydrolysis with trifluoroacetic acid, said coupling being effected in an aprotic polar solvent and--eliminating, at the end of sequence, all the protector groups by hydrolysis with the aid of a 0.1 to 1M solution of methanesulfonic or trifluoromethanesulfonic acid in trifluoroacetic acid.

    专利号:US-4797469-A
    优先权日:1984-07-10
    标 题:Synthesis of hGRF (Somatocrinin) in liquid phase and intermediate peptides
    发明人:DIAZ JOSEPH; DEMARNE HENRI; RONCUCCI ROMEO; SCHMELCK PAUL-HENRY
    权利人:SANOFI SA
    摘要:A process for the synthesis, in liquid phase and by fragments, of hGRF 1-44 and hGRF 1-40. This process consists in coupling, one after the other and in the order of the sequence of the GRF, (1) on the one hand, the following fragments: -H-Ala-Arg-Ala-Arg-Leu-NH2 called Fragment A hGRF (40-44) or - alaninamide (40) -H-Gln-Glu-Arg-Gly-OH called Fragment B'1 hGRF (36-39) -H-Glu-Ser-Asn-OH called Fragment B'2 hGRF (33-35) -H-Ser-Arg-Gln-Gln-Gly-OH called Fragment C hGRF (28-32) -H-Leu-Gln-Asp-Ile-Met-OH called Fragment D' hGRF (23-27) -H-Arg-Lys-Leu-OH called Fragment E'1 hGRF (20-22) - to obtain the peptide K1 [(hGRF (20-44)] on the corresponding peptide having the sequence (20-40) and (2) on the other hand, the following fragments: -H-Gln-Leu-Ser-Ala called Fragment F1 hGRF (16-19) -H-Tyr-Arg-Lys-Val-Leu-Gly OH called Fragment G1 hGRF (10-15) -H-Ile-Phe-Thr-Asn-Ser-OH called Fragment H1 hGRF (5-9) - to obtain the peptide J [hGRF (5-19)] and thereafter to couple together the peptides J and K1 in order to form the peptide having the sequence hGRF (5-44) or hGRF (5-40) and finally to couple the resulting peptide with the peptide H-Tyr-Ala-Asp-Ala-OH, called fragment I hGRF (1-4).

    专利号:EP-0171315-B1
    优先权日:1984-07-10
    标题:Process for the synthesis of hgrf (somatocrinin) in the liquid phase, and intermediary peptides

    专利号:CA-1267998-A
    优先权日:1983-02-21
    标题:Synthesis of hpgrf (somatocrinin) in liquid phase and intermediate peptides

    专利号:EP-0122818-A1
    优先权日:1983-02-21
    标题:Liquid-phase synthesis of hpGRF (Somatocrinin) and intermediate peptides

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    参考标题:Synthesis Of The Octadecapeptide Corresponding To Positions 32 To 49 Of The Revised Amino Acid Sequence Of Thymopoietin Ii And Its Effect On Low E-Rosette Forming Cells Of An Aged Patient With Chronic Renal Failure.
    作者:Takashi Abiko,Hiroshi Sekino
    摘要:The Octadecapeptide, H-Arg-Lys-Asp-Val-Tyr-Val-Glu-Leu-Tyr-Leu-Gln-Ser-Leu-Thr-Ala-Leu-Lys-Arg-Oh, Corresponding To Positions 32 To 49 Of The Revised Amino Acid Sequence Of Bovine Thymopoietin Ii Was Synthesized By The Azide Condensation Of Three Fragments, (32-36), (37-41) And (42-49), Followed By Deprotection With Hydrogen Fluoride In The Presence Of Anisole-Thioanisole-O-Cresol. The In Vitro Addition Of The Synthetic Thymopoietin Ii (32-49) Significantly Restored The Low E-Rosette Forming Capacity Of Cells From An Aged Patient With Chronic Renal Failure To Normal Levels. The In Vitro Effect Of [gln38, Thr43, Val47]-Thymopoietin Ii (32-49) On The Low E-Rosette Forming Capacity Of Cells From The Aged Patient With Chronic Renal Failure Was Also Compared With That Of The Synthetic Thymopoietin Ii (32-49). The [gln38, Thr43, Val47]-Thymopoietin Ii (32-49) Was Approximately Equipotent With The Synthetic Thymopoietin Ii (32-49) At A Concentration Of 100 μg/ml.

    合成参考文献


    参考文献:10.1177/1087057116635503
    摘要:Voter AF, Manthei KA, Keck JL. A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. J Biomol Screen. 2016 Jul;21(6):626–33.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知